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Abstract
Serogroup C meningococcal (MenC) disease accounts for one-third of all meningococcal cases 
and causes meningococcal outbreaks in the U.S. Quadrivalent meningococcal vaccine conjugated 
to diphtheria toxoid (MenACYWD) was recommended in 2005 for adolescents and high risk 
groups such as military recruits. We evaluated anti-MenC antibody persistence in U.S. military 
personnel vaccinated with either MenACYWD or meningococcal polysaccharide vaccine 
(MPSV4). Twelve hundred subjects vaccinated with MenACYWD from 2006 to 2008 or MPSV4 
from 2002 to 2004 were randomly selected from the Defense Medical Surveillance System. 
Baseline serologic responses to MenC were assessed in all subjects; 100 subjects per vaccine 
group were tested during one of the following six post-vaccination time-points: 5–7, 11–13, 17–
19, 23–25, 29–31, or 35–37 months. Anti-MenC geometric mean titers (GMT) were measured by 
rabbit complement serum bactericidal assay (rSBA) and geometric mean concentrations (GMC) by 
enzyme-linked immunosorbent assay (ELISA). Continuous variables were compared using the 
Wilcoxon rank sum test and the proportion of subjects with an rSBA titer ≥8 by chi-square. Pre-
vaccination rSBA GMT was <8 for the MenACWYD group. rSBA GMT increased to 703 at 5–7 
months post-vaccination and decreased by 94% to 43 at 3 years post-vaccination. GMT was 
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significantly lower in the MenACWYD group at 5–7 months post-vaccination compared to the 
MPSV4 group. The percentage of MenACWYD recipients achieving an rSBA titer of ≥8 decreased 
from 87% at 5–7 months to 54% at 3 years. There were no significant differences between vaccine 
groups in the proportion of subjects with a titer of ≥8 at any time-point. GMC for the 
MenACWYD group was 0.14 µg/mL at baseline, 1.07 µg/mL at 5–7 months, and 0.66 µg/mL at 3 
years, and significantly lower than the MPSV4 group at all time-points. Anti-MenC responses 
wane following vaccination with MenACYWD; a booster dose is needed to maintain protective 
levels of circulating antibody.
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1. Introduction
In the United States, serogroups B, C and Y Neisseria meningitidis each account for 
approximately one-third of meningococcal cases [1]. From 1998 to 2007, serogroup C 
(MenC) disease resulted in the highest case fatality ratio (14.6) among the three serogroups 
[1]. MenC often results in more severe sequelae in its survivors and has a predilection to 
cause outbreaks [2–4]. Sequence type (ST) 11/electrophoretic type (ET) 37 clonal complex 
was responsible for outbreaks in U.S. army military recruits in the 1960s and continues to 
cause outbreaks in the U.S. today [1,5]. Although disease rates for all serogroups are at a 
historic low, morbidity and mortality among cases remains unchanged.
Prior to 2005, quadrivalent (A, C, Y, W) meningococcal polysaccharide vaccine, MPSV4 
(Menomune®, Sanofi Pasteur, Swiftwater, PA, USA), was used routinely in U.S. military 
recruits to reduce the risk of disease during basic training. However, routine vaccination of 
the general population was not recommended because of its limited duration of protection. 
In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended 
vaccination of adolescents and other persons at high risk for meningococcal disease with a 
newly licensed quadrivalent meningococcal conjugate vaccine (MenACYW) [6]. Two 
quadrivalent meniningococcal conjugate vaccines are currently available for adolescents in 
the U.S. MenACWYD (Menactra®, diphtheria toxoid conjugate, Sanofi Pasteur, Swiftwater, 
PA, USA) was licensed in 2005 and MenACWYCRM (Menveo™, CRM-197 conjugate, 
Novartis Vaccines, Cambridge, MA, USA) in 2010. The ACIP recommended use of either 
vaccine for adolescents aged 11–18 years and other persons at increased risk for 
meningococcal disease, including military recruits and first year college students living in 
residential housing. Upon licensure, quadrivalent meningococcal conjugate vaccines were 
expected to provide protection for at least 5–10 years. However, a limited number of 
persistence studies conducted during clinical trials suggest antibody waning occurs faster 
than previously predicted [7,8].
To address increasing concern for limited duration of protection following vaccination with 
meningococcal conjugate vaccine, in January 2011 the ACIP recommended a booster dose 
for adolescents on or after their 16th birthday to provide optimal protection throughout the 
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period of increased risk (16–21 years of age). Booster doses continue to be recommended 
every 5 years for high risk groups, such as those with certain immunologic disorders, as well 
as military personnel who continue to be at increased risk [9]. However, data supporting the 
optimal interval for vaccination of these high risk groups are limited. The objective of this 
study is to evaluate antibody persistence to MenC following vaccination with MenACWYD 
in military personnel to inform US public health policy for quadrivalent meningococcal 
vaccines. Serologic responses over a 3 year period are compared to military recruits who 
were routinely vaccinated with meningococcal polysaccharide vaccines (MPSV4) prior to 
licensure of conjugate vaccines.
2. Materials and methods
2.1. Study design and participants
We conducted a retrospective cohort study among U.S. military service personnel previously 
vaccinated with either quadrivalent meningococcal conjugate (MenACWYD) or 
polysaccharide (MPSV4) vaccine. Eligibility criteria included receipt of one dose of MPSV4 
from 2002 to 2004 or MenACWYD from 2006 to 2008, availability of sera prior to 
vaccination, and at least one sample within 3 years post-vaccination. Individuals with a 
history of ≥2 doses of meningococcal vaccine were excluded. Subjects meeting the 
eligibility criteria were selected from the U.S. Department of Defense’s (DoD) Defense 
Medical Surveillance System (DMSS) electronic database. DMSS integrates medical 
surveillance data for over ten million individuals who have served in the U.S. military since 
1990 [10,11]. Sera that had been previously collected and subsequently stored in the 
Department of Defense Serum Repository (DoDSR) as part of public health surveillance 
were used to determine serological responses to meningococcal vaccines.
To determine persistence of antibody responses to MenC following vaccination with MPSV4 
or MenACWYD, 1200 subjects, 600 subjects per vaccination group, were randomly selected 
from DMSS. Basic demographic information, including sex, age and race, and 
meningococcal vaccination history were obtained from DMSS. Pre-vaccination samples 
from all subjects were tested to determine baseline levels. Two hundred subjects, 100 
subjects per vaccination group, were evaluated during one of six post-vaccination time-
points: 5–7 months, 11–13 months, 17–19 months, 23–25 months, 29–31 months, or 35–37 
months. Only one post-vaccination sample per subject was tested.
The study was determined exempt from human subjects research review by the Human 
Subjects Offices at the Naval Health Research Center (NHRC) and Centers for Disease 
Control and Prevention (CDC).
2.2. Serological responses
Serum bactericidal antibody titers to MenC were measured by a validated rabbit complement 
serum bactericidal assay (rSBA) using the target strain C11 [12,13]. Viability counts were 
determined with an automated colony counter (Synbiosis Protocol, United Kingdom). A titer 
of 1.33 was assigned to sera with no activity in the initial serum dilution of 1:4. Continuous 
titers were interpolated from 3-fold serum dilutions. Each sample was assigned a continuous 
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titer resulting in ≥50% killing compared to control wells. The proportion of subjects with 
rSBA titers at or above the putative protective threshold of 8 was calculated [14,15]. A more 
conservative cutoff of 128 was also used to assess decay of immune responses over time. 
Serum IgG anticapsular antibody concentrations were determined using a standardized 
enzyme-linked immunosorbent assay (ELISA) [16]. The concentration of specific IgG 
antibodies in human sera was calculated relative to a human standard reference serum pool, 
CDC 1992 [17]. Antibody concentrations below the lower limit of quantitation (LLQ) of 
0.001 µg/mL were assigned the LLQ. Data were captured with Gen5™ (BioTek) and 
analyzed using ELISA for Windows (CDC, Atlanta, GA). The percent of subjects with IgG 
antibody concentrations at or above 2 µg/mL was determined [18,19]. Testing was 
performed blinded to vaccine type and time-point.
2.3. Statistical analysis
Sample size calculations with a two-sided alpha of 0.05 and 80% power were based on 
previous adult immunogenicity studies of meningococcal conjugate and polysaccharide 
vaccines to determine the proportion of subjects with a threshold of ≥8 for rSBA titers and 
≥2 µg/mL for IgG responses [8,20]. Statistical analysis was performed using SAS 9.2 (SAS 
Institute Inc., Cary, NC, USA). Geometric mean titers (GMT) for rSBA and geometric mean 
concentrations (GMC) for ELISA were calculated for each vaccine group per time-point. 
Because the log-transformed data were not normally distributed, continuous variables were 
compared using the Wilcoxon rank sum test at each time point. A Chi-square test was used 
to compare categorical variables, including the proportions of subjects with rSBA titers ≥8 
and ≥128, as well as the increase in 4-fold response compared to baseline for each time-
point. Comparisons with a two-sided P value ≤0.05 were considered statistically significant. 
P-values for multiple tests across the seven time points were adjusted for multiple 
comparisons by multiplying tested P-values by 7 and comparing them to 0.05 in a test for 
significance.
3. Results
Among the 1200 subjects evaluated, 83% were male and 68% were white. The mean age at 
the time of vaccination was 20.5 years (range, 17–37) for MenACWYD and 20.0 years for 
MPSV4 (range, 17–34). There were no significant differences in sex and race between 
vaccine groups. Serum bactericidal activity and antibody concentrations to MenC were 
measured for all subjects prior to vaccination. Post-vaccination rSBA titers and antibody 
concentrations were analyzed in 1192 and 1190 subjects, respectively. Reasons for exclusion 
included insufficient volume for testing and failure to pass rSBA acceptance criteria for a 
reportable titer. The number of serum samples excluded was similar between vaccine 
groups.
3.1. MenC serologic responses
Baseline rSBA GMT was <8 for both vaccine groups (Fig. 1a). Five to 7 months after 
vaccination, rSBA GMT increased to 703 and 1557 in MenACWYD and MPSV4 groups, 
respectively. GMT decreased by >93% for both groups by 3 years post-vaccination (GMT 
43 and 85 for MenACWYD and MPSV4 groups, respectively). There were no significant 
Patel et al. Page 4
Vaccine. Author manuscript; available in PMC 2017 December 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
differences in GMT between vaccine groups except at 5–7 months post-vaccination 
(adjusted P < 0.05). GMC were <0.20 µag/mL for both vaccine groups prior to vaccination 
(Fig. 1b). Anti-MenC GMC increased to 1.07 µag/mL in the MenACWYD group and 6.00 
µg/mL in the MPSV4 group 5–7 months after vaccination. By 3 years post-vaccination, 
GMC decreased by 38% (0.66 µg/mL) for MenACWYD and 51% (2.95 µg/mL) for MPSV4. 
GMC were significantly different between vaccine groups for all time-points, with the 
conjugate vaccine resulting in lower IgG antibody concentrations than the polysaccharide 
vaccine (adjusted P < 0.0035).
3.2. Proportion of subjects above a given threshold for Men C
The percentages of subjects achieving a serum bactericidal titer of ≥8 and ≥128 against 
MenC and a 4-fold rise compared to base-line are shown in Table 1. The proportion of 
subjects in both vaccine groups with titers ≥8 and ≥128 at 3 years compared to 5–7 months 
post-vaccination decreased by 29–38% and 35–43%, respectively. There were no significant 
differences between vaccine groups in the proportion of subjects with a titer of ≥8, ≥128, or 
4-fold increase from baseline at any time-point. The proportion of subjects with MenC 
antibody concentrations ≥2.0 µg/mL was significantly lower in the MenACWYD group at all 
post-vaccination time-points (Table 2).
4. Discussion
This large-scale observational study of antibody persistence to MenC in U.S. military 
personnel demonstrates waning of immunity within 3 years following vaccination with 
either MenACWYD or MPSV4. No significant differences between the two vaccine groups 
were observed in the percentage of subjects at or above an rSBA titer of 8, the putative 
protective level for MenC. Lower antibody concentrations among MenACWYD recipients 
may be explained by the quantity of antigen in each vaccine as MenACWYD contains 1/10 
the serogroup C antigen of MPSV4. Despite lower antibody concentrations, functional 
activity (as measured by rSBA) was comparable between vaccine groups, suggesting other 
immunologic responses elicited by conjugate vaccines likely contribute to overall protection. 
Conjugate vaccines are T-dependent and therefore induce immunologic memory and more 
rapid anamnestic responses after repeated doses, with antibody level typically several folds 
greater than after initial vaccination. This boost response has been demonstrated after a 
repeat dose of MenACWYCRM 5 years after primary vaccination [21]. Additionally, avidity 
maturation following initial vaccination elicits highly specific antibodies with greater 
bactericidal activity, and could thus explain the similarity in rSBA response despite 
significantly different antibody concentrations between vaccine groups.
The importance of maintaining circulating antibodies to prevent MenC disease has been 
reported in monovalent MenC conjugate vaccine post-licensure studies in the United 
Kingdom [22,23]. Previously vaccinated subjects that developed MenC disease 
demonstrated antibody levels and bactericidal activity comparable to unvaccinated patients, 
despite evidence of immunologic memory [22]. Anamnestic responses can take up to 5 days 
to develop and thus may not be sufficiently rapid enough to prevent disease [23].
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Several U.S. studies have evaluated MenC antibody persistence greater than 1 year following 
vaccination with quadrivalent conjugate vaccines in adolescents [7,8,21]. These studies were 
conducted as extension studies within clinical trials, evaluated antibody persistence in <500 
subjects per study, and provided duration of antibody response for only one time-point post-
vaccination. Serologic responses varied between studies and could be attributed to 
differences in study population, type of protein conjugate used in the vaccines, and assay 
methods and reagents (e.g., complement source). Despite these differences, these studies 
demonstrated waning of immunity to MenC of 60–72%, 35–80%, and 56% at 2, 3 and 5 
years after vaccination, respectively. Additionally, one of the studies suggested early 
evidence of waning at 2 years following vaccination MenACWYD and MenACWYCRM, 
regardless of brand type [7]. Evaluation of immune responses during the first month 
following vaccination was not conducted in our study; however, we were able to 
demonstrate an antibody decay of over 93% in anti-MenC serum bactericidal activity and 
over 38% in antibody concentrations during multiple sampling periods between 6 months 
and 3 years following vaccination with MenACWYD.
Preliminary estimates from a quadrivalent meningococcal conjugate vaccine effectiveness 
(VE) study conducted in over 60% of the US population demonstrates a decrease in VE 
from 82% (CI = 54%–93%) for adolescents vaccinated <1 year earlier to 59% (CI = 5%–
83%) for those vaccinated 3 to <6 years earlier [24]. These data correlate well with our study 
in which almost half of MenACWYD recipients did not demonstrate putative protective titers 
3 years following a single dose.
This study supports the recent ACIP recommendation for a booster dose of meningococcal 
conjugate vaccine for adolescents to maintain protection through late adolescence. Decay in 
antibody responses following a single dose of MenACWYD should be used to inform policy 
recommendations regarding repeat vaccination among military personnel at increased risk. 
As the routine adolescent booster dose is implemented, continued vaccine effectiveness 
studies, disease surveillance, and antibody persistence studies will be important to evaluate 
the impact of the booster dose on duration of protection.
Acknowledgments
We thank Doug Avery, for assistance with quality assurance of serum bactericidal assays, and Julianne Nielsen of 
the Naval Health Research Center who performed confirmatory assays. We are grateful to the Armed Forces Health 
Surveillance Center and the Department of Defense Serum Repository for providing the specimens and respective 
data. The views expressed in this work are those of the authors and do not reflect the official policy of the 
Department of the Navy, Department of Defense, or the US Government. Approved for public releases; distribution 
is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the 
protection of human subjects in research. This work was performed with institutional support provided by the 
Military Vaccine Agency (MILVAX), Military Infectious Diseases Research Program (MIDRP), contract 
#W911QY-08-D-022.
Abbreviations
ACIP Advisory Committee on Immunization Practices
CDC Centers for Disease Control and Prevention
DMSS Defense Medical Surveillance System
Patel et al. Page 6
Vaccine. Author manuscript; available in PMC 2017 December 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DoD Department of Defense
DoDSR Department of Defense Serum Repository
ELISA enzymelinked immunosorbent assay
GMC geometric mean concentration
GMT geometric mean titer
LLQ lower limit of quantitation
MenACYW quadrivalent meningococcal conjugate vaccine
MenACYWDquadrivalent meningococcal conjugate vaccine conjugated to diphtheria 
toxoid
MenC Serogroup C Neisseria meningitidis
MPSV4 quadrivalent meningococcal polysaccharide vaccine
NHRC Naval Health Research Center
rSBA rabbit complement serum bactericidal assay
VE vaccine effectiveness
References
1. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria 
meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of 
meningococcal disease. Clin Infect Dis. 2010 Jan; 50(2):184–91. [PubMed: 20001736] 
2. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 
1990–1994. Clin Infect Dis. 1998 May; 26(5):1159–64. [PubMed: 9597245] 
3. Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties 
of the ET-37 complex of Neisseria meningitidis. J Infect Dis. 1993 Jun; 167(6):1320–9. [PubMed: 
8501321] 
4. Macneil JR, Thomas JD, Cohn AC. Meningococcal disease: shifting epidemiology and genetic 
mechanisms that may contribute to serogroup C virulence. Curr Infect Dis Rep. 2011 Aug; 13(4):
374–9. [PubMed: 21603878] 
5. Artenstein MS, Schneider H, Tingley MD. Meningococcal infections. 1. Prevalence of serogroups 
causing disease in US Army personnel in 1964–70. Bull World Health Organ. 1971; 45(3):275–8. 
[PubMed: 5004110] 
6. Bilukha OO, Rosenstein N. Preventionand control of meningococcal disease recommendations of 
the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2005 May; 
54(RR-7):1–21.
7. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single 
dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine 
(Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccin. 2010 Nov; 6(11):881–7. 
[PubMed: 21339701] 
8. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and 
immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria 
toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005 Oct; 
159(10):907–13. [PubMed: 16203934] 
Patel et al. Page 7
Vaccine. Author manuscript; available in PMC 2017 December 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. Broderick MP, Faix DJ, Hansen CJ, Blair PJ. Trends in meningococcal disease in the United States 
military, 1971–2010. Emerg Infect Dis. 2012 Sep; 18(9):1430–7. [PubMed: 22932005] 
10. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of 
Defense serum repository: glimpses of the future of public health surveillance. Am J Public 
Health. 2002 Dec; 92(12):1900–4. [PubMed: 12453804] 
11. Armed Forces Health Surveillance Center. Fiscal Year 2011 Report. 2011. Available from: http://
www.afhsc.mil/viewDocument?file=AFHSC_AnnualReport_WEB.pdf
12. Borrow R, Carlone GM, Serogroup B. C serum bactericidal assays. Methods Mol Med. 2001; 
66:289–304. [PubMed: 21336762] 
13. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. 
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C 
serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997 Mar; 
4(2):156–67. [PubMed: 9067649] 
14. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for 
meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in 
England. Clin Diagn Lab Immunol. 2003 Sep; 10(5):780–6. [PubMed: 12965904] 
15. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C 
bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003 Mar; 21(11–
12):1094–8. [PubMed: 12559785] 
16. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, Plikaytis BD, et al. Multicenter 
comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels 
measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol. 1994 Jun; 
32(6):1475–82. [PubMed: 8077392] 
17. Holder PK, Maslanka SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM. Assignment of Neisseria 
meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new 
standard reference serum CDC1992. Clin Diagn Lab Immunol. 1995 Mar; 2(2):132–7. [PubMed: 
7697519] 
18. Makela PH, Kayhty H, Weckstrom P, Sivonen A, Renkonen OV. Effect ofgroup-A meningococcal 
vaccine in army recruits in Finland. Lancet. 1975 Nov; 2(7941):883–6. [PubMed: 53370] 
19. Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, et al. Clinical efficacy of 
meningococcus group A capsular polysaccharide vaccine in children three months to five years of 
age. N Engl J Med. 1977 Sep; 297(13):686–91. [PubMed: 408682] 
20. Zangwill KM, Stout RW, Carlone GM, Pais L, Harekeh H, Mitchell S, et al. Duration of antibody 
response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis. 
1994 Apr; 169(4):847–52. [PubMed: 8133100] 
21. Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and 
response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in 
adolescents. Pediatr Infect Dis J. 2012 Oct.
22. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and 
immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J 
Infect Dis. 2006 Dec; 194(12):1745–52. [PubMed: 17109348] 
23. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al. Serogroup C meningococcal 
glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the 
immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006 
Dec; 43(11):1387–94. [PubMed: 17083009] 
24. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention 
and control of meningococcal disease: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Mar; 62(RR-2):1–28.
Patel et al. Page 8
Vaccine. Author manuscript; available in PMC 2017 December 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Box plots of (A) serum bactericidal titers measured by rSBA and (B) antibody 
concentrations measured by ELISA to MenC by months post-vaccination in MenACWYD 
(gray bars) or MPSV4 (white bars) vaccine recipients. The box is defined by the 25th and 
75th percentiles of the distribution; the horizontal line within the box represents the median 
or 50th percentile and the star (asterisk (*)) signifies the mean. Vertical lines extend to the 
most extreme observation that is less than 1.5× the interquartile distance (75th–25th 
percentiles) and the diamonds (◇) and boxes (□) correspond to moderate and severe 
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outlying assay values, respectively. Cross bars (†) denote statistical significance (P < 0.05) 
between vaccine groups for that time-point.
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Table 2
Proportion of subjects with antibody concentration ≥2 µg/mL to meningococcal serogroup C by time since 
vaccination with MenACWYD or MPSV4.
Months after vaccination Number of subjects Percent with anti-MenC IgG ≥2 µg/mL
MenACWYD MPSV4 MenACWYD MPSV4
Pre 600 600 10 7
5–7a 98 99 39 75
11–13a 99 99 34 67
17–19a 99 100 22 70
23–25a 100 99 23 59
29–31a 99 98 22 62
35–37a 100 100 37 67
aP < 0.05, level of significance.
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